


6. APPENDICE

6.3 Mappa SDR-FBE Aree vs ASL

Indice


Tutte le cause (000-999)	Pag. 3
Tumori Maligni (140-208)	Pag. 4
Tumori dello Stomaco (151)	Pag. 5
Tumori del Colon e retto (153, 154)	Pag. 6
Tumori della Pleura (163)	Pag. 7
Tumori dell' app. respiratorio (esclusa Pleura) (160-165)	Pag. 8
Tumori della Mammella donne (174)	Pag. 9
Tumori della Prostata (185)	Pag. 10
Tumori della Encefalo e altri nas (191-192)	Pag. 11
Linfomi (200-202)	Pag. 12
Mieloma (203)	Pag. 13
Tutte le leucemie (204-208)	Pag. 14
Malattie neurologiche (330-349)	Pag. 15
Malattie cardiovascolari (390-459)	Pag. 16
Malattie Cardiache (390-429)	Pag. 17
Eventi coronarici acuti (410-411)	Pag. 18
Scompenso cardiaco (428)	Pag. 19
Malattie Cerebrovascolari (430-438)	Pag. 20
Malattie app. respiratorio (460-519)	Pag. 21
Infezioni acute delle vie respiratorie, polmonite e influenza (460-466,480-487)	Pag. 22
Broncopneumopatia Cronico-Ostruttiva (BPCO) (490-492,494,496)	Pag. 23
Asma (493)	Pag. 24
Asma- Fascia d'età 0-14 anni (493)	Pag. 25

Tutte le cause (000-999)




M	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
F	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tutti i tumori maligni (140-208)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumore dello stomaco (151)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumore del colon-retto (153,154)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumore della pleura (163)




M	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
F	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumori respiratori (160-162, 164-165)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumore della mammella (174)




M	MLE/FBE	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	PPB	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
F	MLE/FBE	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	PPB	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumore della prostata (185)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Tumori dell'encefalo (191-192)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Linfomi (200-202)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Mieloma multiplo (203)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Leucemie (204-208)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Malattie neurologiche (330-349)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Malattie cardio-vascolari (390-459)




M	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
F	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Malattie cardiologiche (390-429)




M	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
F	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Eventi coronarici acuti (410-411)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Scompenso cardiaco (428)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Malattie cerebro-vascolari (430-438)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Malattie respiratorie (460-519)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Infezioni respiratorie (460-466,480-487)




<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Bronco-pneumopatia cronico-ostruttiva (490-492,494-496)




M	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
F	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Asma (493)



<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80

Asma età pediatrica (493)



<i>M</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80
<i>F</i>	<i>MLE/FBE</i>	≤ 0.50	0.51-0.90	0.91-1.10	1.11-1.50	> 1.50
	<i>PPB</i>	≤ 0.20	0.21-0.40	0.41-0.60	0.61-0.80	> 0.80